Ferrándiz C, Carrascosa J M, Just M, Bielsa I, Ribera M
Servei de Dermatologia, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.
Dermatology. 1997;195(4):359-61. doi: 10.1159/000245988.
Prurigo nodularis (PN) is a chronic disease of which treatment choices are limited. Among them, thalidomide and phototherapy have been used with satisfactory results. Unfortunately, the possibility of side effects limits their use.
To evaluate the efficacy of a sequential combined treatment with thalidomide and ultraviolet B (UVB) therapy in order to minimize side effects and, thus, making possible a long-term treatment.
A prospective open trial combining thalidomide as initial therapy followed by narrow-band UVB (TL01) irradiation until complete or almost complete remission of the disease was achieved.
An excellent response was obtained after an average of 12 weeks of thalidomide therapy and 32 UVB courses.
Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age.
结节性痒疹（PN）是一种治疗选择有限的慢性疾病。其中，沙利度胺和光疗已被使用且效果令人满意。不幸的是，副作用的可能性限制了它们的使用。
评估沙利度胺与紫外线B（UVB）疗法序贯联合治疗的疗效，以尽量减少副作用，从而实现长期治疗。
进行一项前瞻性开放试验，以沙利度胺作为初始治疗，随后进行窄谱UVB（TL01）照射，直至疾病完全或几乎完全缓解。
沙利度胺治疗平均12周和32次UVB疗程后获得了极佳的反应。
沙利度胺与窄谱UVB疗法序贯联合治疗可改善结节性痒疹的治疗，副作用最小，尽管可能应仅限于50岁以上的男性和女性。
